S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
TSE:MDP

Medexus Pharmaceuticals - MDP Stock Forecast, Price & News

C$2.02
-0.16 (-7.34%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
C$2.02
▼
C$2.10
50-Day Range
C$0.89
▼
C$2.42
52-Week Range
C$0.88
▼
C$3.45
Volume
12,101 shs
Average Volume
29,806 shs
Market Capitalization
C$40.41 million
P/E Ratio
11.22
Dividend Yield
N/A
Price Target
C$5.50

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Receive MDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDP Stock News Headlines

November 11, 2022 | finance.yahoo.com
Medexus Pharmaceuticals Second Quarter 2023 Earnings: Beats Expectations
November 8, 2022 | finance.yahoo.com
Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022
October 6, 2022 | finance.yahoo.com
Medexus Announces Preliminary Revenue Results for Second Fiscal Quarter 2023
September 19, 2022 | finance.yahoo.com
Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update
September 15, 2022 | finance.yahoo.com
Medexus Holds Annual Meeting of Shareholders and Announces Election of Board of Directors
August 17, 2022 | theglobeandmail.com
Medexus Pharma MDP is in the bottom 25 performing stocks year-to-date on the Toronto Stock Exchange
August 9, 2022 | seekingalpha.com
Medexus Pharmaceuticals Inc. (MEDXF) CEO Ken d'Entremont on Q1 2023 Results - Earnings Call Transcript
August 8, 2022 | finance.yahoo.com
Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022
See More Headlines
Receive MDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDP Company Calendar

Today
12/06/2022
Next Earnings (Estimated)
2/08/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Newspaper Publishers
Sub-Industry
N/A
Sector
Information
Current Symbol
TSE:MDP
CUSIP
N/A
CIK
N/A
Web
www.meredith.com
Phone
15152843000
Fax
N/A
Employees
5,330
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$5.50
High Stock Price Forecast
C$5.50
Low Stock Price Forecast
C$5.50
Forecasted Upside/Downside
+172.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
11.22
Forward P/E Ratio
101.00
P/E Growth
148.5
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
357.40
Current Ratio
0.88
Quick Ratio
0.41

Sales & Book Value

Annual Sales
C$92.27 million
Price / Sales
0.44
Cash Flow
C$0.41 per share
Price / Cash Flow
4.98
Book Value
C$0.85 per share
Price / Book
2.38

Miscellaneous

Outstanding Shares
20,004,000
Free Float
N/A
Market Cap
C$40.41 million
Optionable
Optionable
Beta
N/A

Key Executives

  • Mr. Kenneth d'Entremont
    CEO & Director
  • Mr. Marcel Konrad (Age 46)
    Chief Financial Officer
    Comp: $405.77k
  • Mr. Michael David Adelman (Age 51)
    Gen. Mang., U.S. Operations
    Comp: $491.68k
  • Ms. Tina Byers CFA
    Exec. of Investor Relations
  • Mr. Ian C. Wildgoose Brown
    Gen. Counsel & Corp. Sec.
  • Mr. Bill Poncy
    Sr. VP of Commercial Operations - United States
  • Mr. Brian Peters
    VP of Sales & Marketing - United States

Key Competitors

View All Competitors













MDP Stock - Frequently Asked Questions

Should I buy or sell Medexus Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDP shares.
View MDP analyst ratings or view top-rated stocks.

What is Medexus Pharmaceuticals' stock price forecast for 2023?

2 Wall Street analysts have issued 12-month target prices for Medexus Pharmaceuticals' shares. Their MDP share price forecasts range from C$5.50 to C$5.50. On average, they predict the company's stock price to reach C$5.50 in the next year. This suggests a possible upside of 172.3% from the stock's current price.
View analysts price targets for MDP or view top-rated stocks among Wall Street analysts.

How have MDP shares performed in 2022?

Medexus Pharmaceuticals' stock was trading at C$2.55 at the start of the year. Since then, MDP stock has decreased by 20.8% and is now trading at C$2.02.
View the best growth stocks for 2022 here.

When is Medexus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our MDP earnings forecast.

What is Medexus Pharmaceuticals' stock symbol?

Medexus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDP."

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Medexus Pharmaceuticals' stock price today?

One share of MDP stock can currently be purchased for approximately C$2.02.

How much money does Medexus Pharmaceuticals make?

Medexus Pharmaceuticals (TSE:MDP) has a market capitalization of C$40.41 million and generates C$92.27 million in revenue each year.

How many employees does Medexus Pharmaceuticals have?

The company employs 5,330 workers across the globe.

How can I contact Medexus Pharmaceuticals?

Medexus Pharmaceuticals' mailing address is 1716 Locust St, Des Moines, Iowa 50309-3038. The official website for the company is www.meredith.com. The company can be reached via phone at 15152843000.

This page (TSE:MDP) was last updated on 12/6/2022 by MarketBeat.com Staff